Neuropeptide Y Y1 receptor Structures Offer New Opportunities for Anti-obesity Drug Discovery

News provided by

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Apr 19, 2018, 09:00 ET

-Structures of human neuropeptide Y receptor Y₁R reveal drug recognition mechanisms

SHANGHAI, April 19, 2018 /PRNewswire/ -- Obesity is a major public health concern. Each year, millions of people die from obesity related diseases, such as diabetes and cardiovascular disease. Neuropeptide Y (NPY) is a highly abundant neuropeptide in the central nervous system and participates in a variety of physiological activities, including appetite, energy homeostasis and vascular construction. Four different neuropeptide Y receptors, namely Y₁, Y₂, Y₄ and Y₅ receptors, have been identified in humans. NPY is the most powerful stimulant of food intake, and this effect is primarily mediated by the Y₁ receptor (Y₁R). Thus, Y₁R serves as an important drug target for many human diseases, such as obesity, type 2 diabetes and metabolic syndrome. However, the clinical usage of Y₁R ligands has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability.

The new Nature study reports the structure of the human neuropeptide Y receptor Y1R, which is involved in regulation of food intake and energy homeostasis, and serves as an important drug target for obesity and type 2 diabetes. (Image courtesy of Dr. Beili Wu’s group from SIMM.)

Recently, scientists from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), in collaboration with several groups based in Germany, United States, China and Sweden, determined the high-resolution atomic structures of human Y₁R bound to two structurally diverse antagonists UR-MK299 and BMS-193885, providing a detailed molecular map of Y₁R and invaluable insights into understanding the pharmacology of NPY receptors. The study was published online in Nature on April 18, 2018 (18:00PM, London time) titled "Structural basis of ligand binding modes at the neuropeptide Y Y₁ receptor."

The Y₁R structures reveal, for the first time, the molecular details of an NPY receptor binding to its ligand at atomic level, and provide an accurate template for drug design targeting Y₁R. The structures combined with mutagenesis, ligand binding and signaling studies elucidate the binding modes of Y₁R to various antagonists and the molecular mechanisms of ligand selectivity in different NPY receptors. These findings offer new opportunities for anti-obesity drug discovery.

The NPY-Y receptor system is one of the most complex networks for a GPCR family with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors with different affinity and selectivity. Based on the Y₁R structure, the researchers performed extensive studies including complementary mutagenesis, cell signaling, nuclear magnetic resonance, molecular docking and photo-crosslinking. The results provide insights into the binding behavior of the endogenous agonist NPY to Y₁R, and for the first time identified the binding site of NPY N terminus, which is critical for receptor selectivity, in Y₁R. These insights into Y₁R expand our understanding of NPY receptor signal transduction and lay a foundation for carrying out structure-based drug discovery that targets this physiologically important receptor.

"The Y₁R structures and our functional studies help us understand how this receptor binds to different types of ligands with molecular details. This can enable development of new anti-obesity drugs with better selectivity and efficacy," said team leader and SIMM professor Dr. Beili Wu.

In addition to Dr. Wu, other notable investigators included Dr. Qiang Zhao, Dr. Zhenlin Yang and Dr. Shuo Han from SIMM; Dr. Armin Buschauer and Dr. Max Keller from University of Regensburg; Dr. Annette G. Beck-Sickinger, Dr. Daniel Huster and Dr. Annette Kaiser from Leipzig University; Dr. Jens Meiler and graduate student Brain J. Bender from Vanderbilt University; Dr. Raymond Stevens from the iHuman Institute of ShanghaiTech University; and Dr. Rongguang Zhang from Institute of Biophysics, CAS. The study was funded by Chinese Academy of Sciences, the National Science Foundation of China, the European Community, the Free State of Saxony (Germany), the Deutsche Forschungsgemeinschaft (DFG), National Institute of Health (U.S.A.) and National Science Fundation (U.S.A.).